Dr. Ron Waksman interviews Dr. Michael Reardon on the REPRISE III study outcomes.  REPRISE III study objectives is to evaluate the safety and effectiveness of the Lotus™ Valve System and LOTUS Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with calcific, severe native aortic stenosis who are considered at extreme or high risk for surgical valve replacement.